Ali Dianaty - 09 Mar 2026 Form 4 Insider Report for MiniMed Group, Inc. (MMED)

Role
EVP, Chief Product & Technology Officer
Signature
/s/ Bryan F. Kelly, attorney-in-fact
Issuer symbol
MMED
Transactions as of
09 Mar 2026
Net transactions value
$0
Form type
4
Filing time
11 Mar 2026, 16:30:37 UTC
Previous filing
06 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dianaty Ali EVP, Chief Product & Technology Officer C/O 18000 DEVONSHIRE STREET, NORTHRIDGE /s/ Bryan F. Kelly, attorney-in-fact 11 Mar 2026 0002111492

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MMED Performance-Based Restricted Stock Units Award +13,889 $0.000000* 13,889 09 Mar 2026 Common Stock 13,889 Direct F1, F2
transaction MMED Employee Stock Option (Right to Buy) Award +126,263 $0.000000* 126,263 09 Mar 2026 Common Stock 126,263 $18.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).
F2 The later of March 9, 2027 or the Divestment Date.
F3 The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

Remarks:

EVP, Chief Product & Technology Officer